Apparently, it's no longer the U.S. government that Smithfield Foods (UNKNOWN: SFD.DL ) has to worry about scuttling its purchase by Chinese meat producer Shuanghui International. Analysts say the deal is likely to get approved, albeit with conditions, though the national security fears raised by grandstanding politicians did get some airplay at congressional hearings this past summer.
No, the bigger threat comes from its own investors, namely, private equity firm Starboard Value, its biggest shareholder with a 5.7% stake in the pork processor. It says it plans to vote against the merger, believing the $4.7 billion deal, or $34-per-share offer, does not provide enough value to shareholders, and it seeks more time to pursue other possible options. Including debt, the total value of the acquisition is $7.1 billion.
High on Starboard's agenda would be the piecemeal sale of the company. It said it has in writing offers for different parts of Smithfield's business that would total more than the value of Shuanghui's offer. However, in something of a conciliatory note, the private equity firm said that, while it plans to vote against the merger, if it can't get a third-party deal together, it will ultimately vote in favor of the sale.
Smithfield Foods is the largest pork processor in the country, with $13.2 billion in annual revenue, and a 28% market share, ahead of No. 2 Tyson Foods (NYSE: TSN ) , which generated $5.3 billion in pork revenue over the past 12 months, and has a 17% share. Brazil's JBS is third with an 11% share.
Pork remains the fastest-growing protein segment, according to a study by Technomic, which found that the amount of pork sold through foodservice outlets has grown to a record 9.25 billion pounds annually, a 2.6% increase over 2011, and well ahead of the 0.8% increase in average protein growth.
Earlier this year, Seaboard, which gets 30% of its revenues from the other white meat, bought privately held processor Gusto, suggestive of the popularity pork is experiencing.
Tyson, which like other processors had been relying upon pork's renewed sales spurt to prop up its meat business as chicken and beef slipped, was hurt when China and Russia blocked the import of U.S. pork earlier this year because of the use of ractopamine, a growth-promoting drug that increases lean muscle production in hogs and cattle before they're led to slaughter.
Having lost those markets, and having watched its volumes fall by 2% and 3% in the last two quarters, Tyson announced it would no longer use Zilmax, a drug produced by Merck that's similar to ractopamine, because of the impact it was having on animal health. Smithfield Foods, as a matter of fact, halted the use of ractopamine just before the sale to Shuanghui was announced. Now, Merck has suspended sales of the drug, and other meat producers like Cargill have also said they'll end their use of the fattening agent.
While I thought 2013 would be the year to invest in pork -- and I thought Smithfield was the best bet of them all, though admittedly, because of industry trends, not as a takeover candidate -- it seems there's still plenty of meat on the bone with this industry, and it wouldn't be surprising to see Starboard Value come through with a better plan.
Because consumers continue to turn in greater numbers to pork for their protein needs, investors would do well to seek out other possibilities here. Pork prices are higher, hurting companies like Hormel and Hillshire Brands, which saw higher input costs weigh on results. But despite the downturn due to the loss of some international markets, Tyson is my next favorite in the space.
With a broad portfolio of meats to smooth out any vagaries due to an outbreak of swine flu or mad cow disease, and with Smithfield Foods likely going away one way or the other, Tyson could be an investor's other pork choice.